CVXL-0101

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCVXL-0101
Drug Alias Namedual SYK/JAK3 inhibitor (CleveXel Pharma)CVXL-0101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsSpleen tyrosine kinase inhibitors
TargetsTyrosine-protein kinase JAK3Spleen tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesClevexel Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClevexel Pharma
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A